Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer.

Additionally, patients who took Statins and Cox2 inhibitors while receiving Gem showed a trend toward better survival outcomes compared to those who received combinatorial chemotherapy with albumin-bound paclitaxel (Nab-paclitaxel) plus Gem, which is the current standard therapy for PDAC patients, as well as better survival outcomes than those who received FOLFIRINOX, the most powerful chemotherapy regimen for treating advanced PDAC (Fig. 8e ).

also in 53,322 other papers